<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rpmj</journal-id><journal-title-group><journal-title xml:lang="ru">Research'n Practical Medicine Journal</journal-title><trans-title-group xml:lang="en"><trans-title>Research and Practical Medicine Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2410-1893</issn><publisher><publisher-name>"QUASAR", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17709/2409-2231-2018-5-4-10</article-id><article-id custom-type="elpub" pub-id-type="custom">rpmj-327</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Клиническое наблюдение</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Clinical Case Reports</subject></subj-group></article-categories><title-group><article-title>Возможности лечения диссеминированной меланомы с множественным метастатическим поражением головного мозга</article-title><trans-title-group xml:lang="en"><trans-title>A case of long-term disease control in a patient with disseminated melanoma with synchronous detection of multiple brain metastases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куржупов</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurzhupov</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Куржупов Михаил Иванович - кандидат медицинских наук, заведующий онкологическим отделением ГБУЗ «Клинико-диагностический центр №4» Департамента здравоохранения г. Москвы, врач-нейрохирург РНЦР.</p></bio><bio xml:lang="en"><p>Mikhail I. Kurzhupov  - MD, PhD, head of Oncology Department, CDC No. 4 of the Moscow Healthcare Department, neurosurgeonRSCR.</p><p>3 Krylatskie kholmy str., Moscow 121609</p></bio><email xlink:type="simple">kmim@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ГБУЗ «Клинико-диагностический центр №4» Департамента здравоохранения г. Москвы; ФГБУ «Российский научный центр рентгенорадиологии» Министерства здравоохранения Российской Федерации<country>Россия</country></aff><aff xml:lang="en">Clinical Diagnostic Center No. 4 of the Moscow Healthcare Department; Russian Scientific Center of Roentgenoradiology<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2018</year></pub-date><volume>5</volume><issue>4</issue><fpage>98</fpage><lpage>105</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Куржупов М.И., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Куржупов М.И.</copyright-holder><copyright-holder xml:lang="en">Kurzhupov M.I.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpmj.ru/rpmj/article/view/327">https://www.rpmj.ru/rpmj/article/view/327</self-uri><abstract><p>В статье приводятся современные результаты клинических исследований лечения метастатической меланомы с поражением головного мозга. Обсуждается клинический случай длительной выживаемости пациентки с диссеминированной меланомой кожи и синхронным множественным метастатическим поражением головного мозга за счет контроля опухолевого заболевания с использованием современного противоопухолевого лечения, включающего таргетную терапию, иммунотерапию, лучевую терапию, радиохирургию и нейрохирургию (на этапе диагностики). Продолжительность жизни пациентки с момента выявления заболевания составила 22 мес, при ожидаемой 2-3 мес.</p></abstract><trans-abstract xml:lang="en"><p>The article presents clinical trials data of melanoma with brain metastasis and a clinical case of long-term survival of a patient with disseminated skin melanoma and synchronous multiple metastatic brain damage by controlling a tumor disease using modern antitumor treatment, including targeted therapy, immunotherapy, radiation therapy, radiosurgery and neurosurgery (at the stage of diagnosis). The total duration of life after detection of the disease is 22 months, with an expected 2-3 months.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>меланома кожи</kwd><kwd>внутримозговые метастазы</kwd><kwd>таргетная терапия</kwd><kwd>иммунотерапия</kwd><kwd>радиохирургия</kwd><kwd>лучевая терапия</kwd><kwd>нейрохирургия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>skin melanoma</kwd><kwd>brain metastases</kwd><kwd>targeted therapy</kwd><kwd>immunotherapy</kwd><kwd>radiosurgery</kwd><kwd>radiation therapy</kwd><kwd>neurosurgery</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Коршунов А. Г. Классификация опухолей нервной системы. Клиническая неврология. Под редакцией А. Н. Коновалова. Том III. М., 2014, 171 pp.</mixed-citation><mixed-citation xml:lang="en">Korshunov A. G. Klassifikatsiya opukholei nervnoi sistemy. Klinicheskaya nevrologiya [Classification of tumors of the nervous system. Clinical neurology]. Edited by A. N. Konovalov. Vol. III.	Мoscow, 2014, 171 pp. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Larson D, Rubenstein JM, McDermott, Asbell S, Phillips T, Was-serman T, et al. Treatment of Metastatic Cancer: Cancer Principles and Practice of Oncology. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. 2323-2398 pp.</mixed-citation><mixed-citation xml:lang="en">Larson D, Rubenstein JM, McDermott, Asbell S, Phillips T, Was-serman T, et al. Treatment of Metastatic Cancer: Cancer Principles and Practice of Oncology. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. 2323-2398 pp.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997 Mar 1;37 (4):745-51. DOI: 10.1016/j.ctrv.2004.05.001</mixed-citation><mixed-citation xml:lang="en">Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997 Mar 1;37 (4):745-51. DOI: 10.1016/j.ctrv.2004.05.001</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А. Д., Старинский В. В., Петрова В. В. Состояние онкологической помощи населению России в 2016 году. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИРЦ» Минздрава России, 2017, 266 с.</mixed-citation><mixed-citation xml:lang="en">Kaprin AD, Starinskii VV, Petrova VV. State of cancer care to the population of Russia in 2016. Мoscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation, 2017, 266 p. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev. 2004 Oct;30 (6):515-20.</mixed-citation><mixed-citation xml:lang="en">Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev. 2004 Oct;30 (6):515-20.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control. 2009 Jul;16 (3):248—55. DOI: 10.1177/107327480901600307</mixed-citation><mixed-citation xml:lang="en">Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control. 2009 Jul;16 (3):248-55. DOI: 10.1177/107327480901600307</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Акимов М. А., Гершанович М. Л. Клиническая оценка эффективности современных режимов химиотерапии первой, второй и третьей линии у больных диссеминированной меланомой кожи. Вопросы онкологии. 2001;47 (4):428-35.</mixed-citation><mixed-citation xml:lang="en">Akimov M. A., Gershanovich M. L. Klinicheskaya otsenka ef-fektivnosti sovremennykh rezhimov khimioterapii pervoi, vto-roi i tret'ei linii u bol'nykh disseminirovannoi melanomy kozhi. Voprosy oncologii (Problems in Oncology). 2001;47 (4):428-35. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Gonzalez-Martinez J, Hernandez L, Zamorano L, Sloan A, Levin K, Lo S, Li Q, Diaz F. Gamma knife radiosurgery for intracranial metastatic melanoma: a 6-year experience. J Neurosurg. 2002 Dec;97 (5 Suppl):494-8.</mixed-citation><mixed-citation xml:lang="en">Gonzalez-Martinez J, Hernandez L, Zamorano L, Sloan A, Levin K, Lo S, Li Q, Diaz F. Gamma knife radiosurgery for intracranial metastatic melanoma: a 6-year experience. J Neurosurg. 2002 Dec;97 (5 Suppl):494-8.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">National Comprehensive Cancer Network. Central nervous system cancers. NCCN Guidelines. Version 1.2013. 2012.</mixed-citation><mixed-citation xml:lang="en">National Comprehensive Cancer Network. Central nervous system cancers. NCCN Guidelines. Version 1.2013. 2012.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Насхлеташвили Д. Р., Банов С. М., Бекяшев А. Х., Борисова Т. Н., Ветлова Е. Р., Голанов А. В., Зайцев А. М., Кобя-ков Г. Л., Назаренко А. В., Смолин А. В. Практические рекомендации по лекарственному лечению метастатических опухолей головного мозга. Злокачественные опухоли: Практические рекомендации RUSSCO. 2017;7 (S2):93-104. DOI: 10.18027/2224—5057—2017—7-3s2—93-l04</mixed-citation><mixed-citation xml:lang="en">Naskhletashvili DR, Banov SM, Bekyashev AK, et al. Practical guiedlines of systemic treatment of cancer brain me-tastases. Malignant Tumoursis. 2017;7 (S2):93-104. DOI: 10.18027/2224-5057-2017-7-3s2-93-l04</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAFV600-mu-tant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017 Jul;18 (7):863-873. DOI: 10.1016/S1470-2045(17)30429-1</mixed-citation><mixed-citation xml:lang="en">Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAFV600-mu-tant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017 Jul;18 (7):863-873. DOI: 10.1016/S1470-2045(17)30429-1</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys RAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov;13 (11):1087-95. DOI: 10.1016/S1470-2045(12)70431-X.</mixed-citation><mixed-citation xml:lang="en">Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov;13 (11):1087-95. DOI: 10.1016/S1470-2045(12)70431-X.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Goldberg SB, Geffinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016 Jul;17 (7):976-983. DOI: 10.1016/S1470-2045 (16)30053-5.</mixed-citation><mixed-citation xml:lang="en">Goldberg SB, Geffinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016 Jul;17 (7):976-983. DOI: 10.1016/S1470-2045(16)30053-5.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 May;19 (5):672-681. DOI: 10.1016/S1470-2045(18)30139-6</mixed-citation><mixed-citation xml:lang="en">Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 May;19 (5):672-681. DOI: 10.1016/S1470-2045(18)30139-6</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 Aug 23;379 (8):722-730. DOI: 10.1056/NEJMoa1805453.</mixed-citation><mixed-citation xml:lang="en">Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 Aug 23;379 (8):722-730. DOI: 10.1056/NEJMoa1805453.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Weber J, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016 Jul;17 (7):943-955. DOI: 10.1016/S1470-2045(16)30126-7</mixed-citation><mixed-citation xml:lang="en">Weber J, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016 Jul;17 (7):943-955. DOI: 10.1016/ S1470-2045(16)30126-7</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
